Indicators
Indicators
Value
Direction
MACD(12,26,9)
-2.537
Sell
RSI(14)
34.712
Neutral
STOCH(KDJ)(9,3,3)
20.198
Neutral
ATR(14)
3.825
High Vlolatility
CCI(14)
-99.236
Neutral
Williams %R
75.200
Sell
TRIX(12,20)
-0.603
Sell
StochRSI(14)
87.391
Buy
Tempus AI Inc
TEM54.910USD
+2.470+4.71%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
9.76BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Tempus AI Inc
Currency: USD Updated: 2026-02-06Key Insights
Tempus AI Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 87.42.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tempus AI Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tempus AI Inc Highlights
StrengthsRisks
Tempus AI, Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. It offers AI-enabled precision medicine solutions to physicians to deliver personalized patient care and, in parallel, facilitates discovery, development and delivery of optimal therapeutics. It provides three product lines: Genomics, Data and artificial intelligence applications (AI). The Genomics product line leverages its laboratories to provide next generation sequencing (NGS) diagnostics, polymerase chain reaction, profiling, molecular genotyping and other anatomic and molecular pathology testing. The data generated in its lab or ingested into its platform is structured and de-identified, prior to commercialization. Its AI Applications is focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 693.40M.
Undervalued
The company’s latest PE is -188.90, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 96.30M shares, increasing 4.83% quarter-over-quarter.
Held by John Hussman
Star Investor John Hussman holds 42.00K shares of this stock.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
87.419
Target Price
+66.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-02-06The current financial score of Tempus AI Inc is 8.46, ranking 42 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 334.21M, representing a year-over-year increase of 84.72%, while its net profit experienced a year-over-year increase of 5.46%.
Score
Financials
6.49
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
8.66
Operational Efficiency
10.00
Growth Potential
9.64
Shareholder Returns
7.52
Tempus AI Inc's Company Valuation
Currency: USD Updated: 2026-02-06The current valuation score of Tempus AI Inc is 7.30, ranking 140 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -188.90, which is -125.50% below the recent high of 48.18 and -51.61% above the recent low of -286.38.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 65/392
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-02-06The current earnings forecast score of Tempus AI Inc is 7.53, ranking 283 out of 392 in the Biotechnology & Medical Research industry. The average price target is 90.00, with a high of 105.00 and a low of 80.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
17
analysts
Buy
Current Rating
87.419
Target Price
+66.70%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
542
Total
6
Median
6
Average
Company name
Ratings
Analysts
Tempus AI Inc
TEM
17
CRISPR Therapeutics AG
CRSP
29
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
24
Intellia Therapeutics Inc
NTLA
24
1
2
3
...
109
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-02-06The current price momentum score of Tempus AI Inc is 6.86, ranking 149 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 70.87 and the support level at 44.42, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
55.084
Sell
MA10
59.776
Sell
MA20
63.738
Sell
MA50
67.129
Sell
MA100
75.290
Sell
MA200
70.048
Sell
Institutional Confidence
Currency: USD Updated: 2026-02-06The current institutional shareholding score of Tempus AI Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 55.71%, representing a quarter-over-quarter increase of 27.17%. The largest institutional shareholder is The Vanguard, holding a total of 10.24M shares, representing 5.92% of shares outstanding, with 66.01% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Blue Media, LLC
BK TL21 LLC
Lefkofsky (Eric Paul)
Gray Media, LLC
Red Sky LLC
SoftBank Group Corp
1
2
Risk Assessment
Currency: USD Updated: 2026-02-06The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Tempus AI Inc is 4.78, ranking 70 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.
Score
Beta vs S&P 500 index
--
VaR
--
240-Day Maximum Drawdown
+49.21%
240-Day Volatility
+87.64%
Return
Best Daily Return
60 days
+8.21%
120 days
+13.59%
5 years
--
Worst Daily Return
60 days
-5.81%
120 days
-12.36%
5 years
--
Sharpe Ratio
60 days
-1.78
120 days
-0.59
5 years
--
Risk Assessment
Maximum Drawdown
240 days
+49.21%
3 years
--
5 years
--
Return-to-Drawdown Ratio
240 days
-0.43
3 years
--
5 years
--
Skewness
240 days
+0.22
3 years
--
5 years
--
Volatility
Realised Volatility
240 days
+87.64%
5 years
--
Standardised True Range
240 days
+8.79%
5 years
--
Downside Risk-Adjusted Return
120 days
-113.59%
240 days
-113.59%
Maximum Daily Upside Volatility
60 days
+48.18%
Maximum Daily Downside Volatility
60 days
+41.30%
Liquidity
Average Turnover Rate
60 days
+6.09%
120 days
+6.82%
5 years
--
Turnover Deviation
20 days
--
60 days
--
120 days
--
Peer Comparison
Biotechnology & Medical Research
Tempus AI Inc
TEM
7.07 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.60 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ionis Pharmaceuticals Inc
IONS
8.38 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.37 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.17 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
